207 related articles for article (PubMed ID: 12823076)
1. Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
Opolka JL; Rascati KL; Brown CM; Barner JC; Johnsrud MT; Gibson PJ
J Clin Psychiatry; 2003 Jun; 64(6):635-9. PubMed ID: 12823076
[TBL] [Abstract][Full Text] [Related]
2. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
Opolka JL; Rascati KL; Brown CM; Gibson PJ
Psychiatr Serv; 2004 Feb; 55(2):151-6. PubMed ID: 14762239
[TBL] [Abstract][Full Text] [Related]
3. Role of ethnicity in predicting antipsychotic medication adherence.
Opolka JL; Rascati KL; Brown CM; Gibson PJ
Ann Pharmacother; 2003 May; 37(5):625-30. PubMed ID: 12708934
[TBL] [Abstract][Full Text] [Related]
4. Racial disparity in the use of atypical antipsychotic medications among veterans.
Copeland LA; Zeber JE; Valenstein M; Blow FC
Am J Psychiatry; 2003 Oct; 160(10):1817-22. PubMed ID: 14514496
[TBL] [Abstract][Full Text] [Related]
5. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States.
Daumit GL; Crum RM; Guallar E; Powe NR; Primm AB; Steinwachs DM; Ford DE
Arch Gen Psychiatry; 2003 Feb; 60(2):121-8. PubMed ID: 12578429
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia.
Kuno E; Rothbard AB
Am J Psychiatry; 2002 Apr; 159(4):567-72. PubMed ID: 11925294
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.
Arnold JG; Miller AL; Cañive JM; Rosenheck RA; Swartz MS; Mintz J
Psychiatr Serv; 2013 Jun; 64(6):570-8. PubMed ID: 23494108
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
[TBL] [Abstract][Full Text] [Related]
12. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
[TBL] [Abstract][Full Text] [Related]
13. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Revicki DA; Genduso LA; Hamilton SH; Ganoczy D; Beasley CM
Qual Life Res; 1999 Aug; 8(5):417-26. PubMed ID: 10474283
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
[TBL] [Abstract][Full Text] [Related]
19. Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.
Dusetzina SB; Cook BL; Busch AB; Alexander GC; Huskamp HA
Psychiatr Serv; 2013 Jan; 64(1):83-7. PubMed ID: 23280461
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
